Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-centre Phase II Clinical Study of Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

NCT06764251 is registered in ClinicalTrials.gov with Liaoning Cancer Hospital & Institute as lead sponsor.

NCT NCT06764251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06764251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-centre Phase II Clinical Study of Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma
Lead sponsor
Liaoning Cancer Hospital & Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 30, 2024
Completion date
March 31, 2028
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric/gastroesophageal junction adenocarcinoma